CellBion Co., Ltd. (KOSDAQ:308430)

South Korea flag South Korea · Delayed Price · Currency is KRW
16,600
-530 (-3.09%)
Last updated: Oct 17, 2025, 9:00 AM KST
-3.09%
Market Cap204.84B
Revenue (ttm)2.63B
Net Income (ttm)-7.43B
Shares Out12.82M
EPS (ttm)-665.27
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume305,340
Average Volume249,198
Open17,120
Previous Close17,130
Day's Range16,600 - 17,380
52-Week Range9,930 - 29,600
Betan/a
RSI30.55
Earnings DateNov 13, 2025

About CellBion

CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphos... [Read more]

Industry Pharmaceutical Preparations
Founded 2010
Employees 57
Stock Exchange KOSDAQ
Ticker Symbol 308430
Full Company Profile

Financial Performance

In 2024, CellBion's revenue was 2.29 billion, an increase of 55.64% compared to the previous year's 1.47 billion. Losses were -7.27 billion, 100.0% more than in 2023.

Financial Statements

News

There is no news available yet.